Immunotherapy in non-small cell lung cancer: Update and new insights.

ABSTRACT:

Background

The treatment of non-small-cell lung carcinoma (NSCLC) has changed markedly in recent years as a result of two major treatment milestones: Targeted therapy and immunotherapy. Since 2015, immunotherapy has been changing the paradigm of NSCLC treatment in different settings and has contributed to improve the quality of life of these patients. The most widely used immunotherapy strategy in clinical practice is currently PD-1 and CTLA-4 immune checkpoint inhibition-based immunotherapy. Initial successful results came from an improvement in overall survival for pretreated patients, and immunotherapy subsequently moved to a first-line palliative setting as monotherapy, in combination with chemotherapy or as double-checkpoint inhibition. With regard to earlier stages, consolida

SUBMITTER: Mielgo-Rubio X 

PROVIDER: S-EPMC8177026 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature